Aspire-Lakewood (ASBP) vs BioLineRx (BLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed BioLineRx (BLRX) over the past year, losing 43.0% versus a loss of 50.3%. Aspire-Lakewood is the larger company by market cap ($11.6 million vs $11.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | BLRX |
|---|---|---|
| Share price | $8.30 | $2.21 |
| Market cap | $11.64M | $11.00M |
| 1-day change | -3.82% | +0.23% |
| YTD return | +57.20% | -20.40% |
| 1-year return | -42.99% | -50.34% |
| 5-year return | — | -98.20% |
| EPS (TTM) | $-30.89 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.76 | $4.50 |
| 52-week low | $0.11 | $2.15 |
| Distance from 52-week high | -55.76% | -50.89% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +895.48% |
| Average volume | 36.92K | 16.27K |
| Shares outstanding | 1.40M | 4.98M |
| Employees | — | 20 |
| Sector | Consumer Cyclical | Healthcare |
| Industry | Auto Parts | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Aspire-Lakewood in Consumer Cyclical and BioLineRx in Healthcare.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Consumer Cyclical · Auto Parts
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Healthcare · Biotechnology · 20 employees
ASBP vs BLRX FAQ
Which is bigger, Aspire-Lakewood or BioLineRx?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $11.64M compared with $11.00M for BioLineRx (BLRX).
Which stock has performed better over the past year, ASBP or BLRX?
ASBP returned -42.99% over the past 12 months, compared with -50.34% for BLRX (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and BioLineRx in the same industry?
No. Aspire-Lakewood is in the Consumer Cyclical sector, while BioLineRx is in Healthcare.